日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Cost-Effectiveness and Public Health Impact of 24-Valent Pneumococcal Conjugate Vaccine Compared With the Recommended Pneumococcal Vaccines in Older Adults

24价肺炎球菌结合疫苗与老年人推荐的肺炎球菌疫苗相比的成本效益和公共卫生影响

Smith, Kenneth J; Wateska, Angela R; Nowalk, Mary Patricia; Lin, Chyongchiou J; Harrison, Lee H; Schaffner, William; Zimmerman, Richard K

A budget impact analysis of 15- or 20- valent pneumococcal conjugate vaccine use in all US adults aged 50-64 years old compared to those with high-risk conditions from US payer perspective

从美国支付方的角度分析15价或20价肺炎球菌结合疫苗在所有50-64岁美国成年人中的使用情况,并与高危人群进行比较,对预算影响。

Vadlamudi, Nirma Khatri; Lin, Chyongchiou J; Wateska, Angela R; Zimmerman, Richard K; Smith, Kenneth J

Cost-effectiveness and budget impact analyses of the 24-valent pneumococcal conjugate vaccine in adults aged 50 and older

对50岁及以上成年人接种24价肺炎球菌结合疫苗的成本效益和预算影响分析

Altawalbeh, Shoroq M; Wateska, Angela R; Nowalk, Mary Patricia; Lin, Chyongchiou J; Harrison, Lee H; Schaffner, William; Zimmerman, Richard K; Smith, Kenneth J

Societal Cost of Racial Pneumococcal Disease Disparities in US Adults Aged 50 Years or Older

美国50岁及以上成年人肺炎球菌疾病种族差异的社会成本

Altawalbeh, Shoroq M; Wateska, Angela R; Nowalk, Mary Patricia; Lin, Chyongchiou J; Harrison, Lee H; Schaffner, William; Zimmerman, Richard K; Smith, Kenneth J

Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older

一项针对美国50岁及以上成年人的在研成人配方21价肺炎球菌结合疫苗的成本效益分析

Altawalbeh, Shoroq M; Wateska, Angela R; Nowalk, Mary Patricia; Lin, Chyongchiou J; Harrison, Lee H; Schaffner, William; Zimmerman, Richard K; Smith, Kenneth J

Corrigendum to "Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older" [Vaccine 42 (2024) 3024-3032]

对“正在研发中的成人配方 21 价肺炎球菌结合疫苗在美国 50 岁及以上成年人中的成本效益”的更正 [疫苗 42 (2024) 3024-3032]

Altawalbeh, Shoroq M; Wateska, Angela R; Patricia Nowalk, Mary; Lin, Chyongchiou J; Harrison, Lee H; Schaffner, William; Zimmerman, Richard K; Smith, Kenneth J

Cost-effectiveness of recombinant influenza vaccine compared with standard dose influenza vaccine in adults 18-64 years of age

重组流感疫苗与标准剂量流感疫苗在18-64岁成人中的成本效益比较

Nowalk, Mary Patricia; Smith, Kenneth J; Raviotta, Jonathan M; Wateska, Angela; Zimmerman, Richard K

Changes in the cost-effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults

美国老年人肺炎球菌疫苗接种及其接种率提高计划的成本效益变化

Wateska, Angela R; Nowalk, Mary Patricia; Altawalbeh, Shoroq M; Lin, Chyongchiou J; Harrison, Lee H; Schaffner, William; Zimmerman, Richard K; Smith, Kenneth J

Pneumococcal Vaccination Strategies in 50-Year-Olds to Decrease Racial Disparities: A US Societal Perspective Cost-Effectiveness Analysis

针对50岁人群的肺炎球菌疫苗接种策略以减少种族差异:美国社会视角下的成本效益分析

Altawalbeh, Shoroq M; Wateska, Angela R; Nowalk, Mary Patricia; Lin, Chyongchiou J; Harrison, Lee H; Schaffner, William; Zimmerman, Richard K; Smith, Kenneth J

Cost-Effectiveness of Newly Recommended Pneumococcal Vaccination Strategies in Older Underserved Minority Adults in the USA

美国老年弱势少数族裔成年人中新推荐的肺炎球菌疫苗接种策略的成本效益分析

Smith, Kenneth J; Wateska, Angela R; Nowalk, Mary Patricia; Lin, Chyongchiou J; Harrison, Lee H; Schaffner, William; Zimmerman, Richard K